Concerns about possible unintended consequences of reference pricing-atleast when applied to ACE inhibitors-appear to be unfounded, according toa new analysis of Canadian data.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Reference pricing does not compromise outcomes of ACE inhibitor therapy

Newsletter